Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Celgene
Celgene
[video+transcript]Here's What's Behind Bristol Myers Squibb's Huge Acquisitions
Motley Fool
Wed, 11/4/20 - 10:12 am
Bristol-Myers Squibb
M&A
Celgene
MyoKardia
Celgene shareholders are parsing blurry photos in search of a payday
Stat
Thu, 10/8/20 - 10:34 am
Celgene
Bristol-Myers Squibb
FDA
M&A
Bristol Myers’ Hirawat on Pipeline Progress, Clinical Trial Diversity
Xconomy
Sun, 10/4/20 - 12:11 am
Bristol-Myers Squibb
Celgene
clinical trials
clinical trial diversity
Samit Hirawat
Congressional investigation reveals Celgene, Teva plotted to keep drug prices high
RAPS.org
Wed, 09/30/20 - 11:08 pm
congress
Celgene
Teva Pharmaceutical
Revlimid
Copaxone
drug pricing
Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week
Fierce Pharma
Tue, 09/22/20 - 10:21 pm
drug pricing
regulatory
Celgene
Bristol-Myers Squibb
Teva Pharmaceutical
Amgen
Novartis
Mallinckrodt
AbbVie
US Congress
FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday
Fierce Biotech
Tue, 09/22/20 - 12:18 pm
Bristol-Myers Squibb
Celgene
Bluebird Bio
FDA
priority review
ide-cel
Ex-Celgene exec steers his biotech startup to Hong Kong IPO as potential cancer drug launch looms
Endpoints
Thu, 08/27/20 - 10:42 am
Celgene
Antengene
IPOs
startups
Jay Mei
Hong Kong
AbbVie's Skyrizi stands to gain as docs move away from older psoriasis meds—Amgen's Otezla included
Fierce Pharma
Tue, 08/25/20 - 11:12 am
psoriasis
AbbVie
Skyrizi
Amgen
Celgene
Otezla
Amgen's psoriasis pill Otezla thrives amid pandemic against injectable rivals
Fierce Pharma
Wed, 07/29/20 - 12:31 pm
Otzela
Celgene
Amgen
psoriasis
COVID-19
After Celgene deal, BMS shoots up pharma market cap rankings
Pharmaforum
Sun, 06/21/20 - 10:51 pm
Bristol-Myers Squibb
Celgene
M&A
Roche's Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study
BioSpace
Thu, 06/18/20 - 08:38 pm
Roche
Genentech
Tecentriq
triple negative breast cancer
clinical trials
Celgene
Abraxane
Bristol's Celgene merger sees it bounce Jounce drug pact
Fierce Biotech
Fri, 06/5/20 - 10:43 am
Bristol-Myers Squibb
Celgene
Jounce Therapeutics
M&A
immuno-oncology
Bristol Myers Squibb's Zeposia launches into crowded MS market
Fierce Pharma
Tue, 06/2/20 - 10:50 am
Bristol-Myers Squibb
Celgene
Zeposia
drug launches
MS
multiple sclerosis
Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout
Motley Fool
Mon, 05/11/20 - 11:36 pm
Bristol-Myers Squibb
Celgene
M&A
Bluebird Bio
Amgen ramps up Otezla expansion effort with positive data in mild psoriasis
Fierce Pharma
Thu, 05/7/20 - 12:27 am
Amgen
Celgene
Otezla
psoriasis
CHMP backs BMS’ first-in-class anemia drug Reblozyl
Pharmaforum
Mon, 05/4/20 - 10:34 am
Bristol-Myers Squibb
EMA
CHMP
Reblozyl
anemia
Celgene
Amgen's anti-inflammatory Otezla makes its foray into COVID-19
Fierce Pharma
Fri, 05/1/20 - 12:47 pm
Amgen
Celgene
Otezla
M&A
COVID-19
Bristol Myers to CEO Caforio: Good job on Celgene so far, but you'll have to work for your raise
Fierce Pharma
Thu, 04/2/20 - 12:00 am
Bristol-Myers Squibb
Celgene
executive pay
Giovanni Caforio
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Endpoints
Tue, 03/31/20 - 10:47 am
Bristol-Meyers Squibb
CAR-T
Celgene
ide-cel
Bluebird Bio
liso-cel
ozanimod
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
Xconomy
Thu, 03/26/20 - 10:42 am
Bristol-Meyers Squibb
Celgene
M&A
ozanimod
MS
mutliple sclerosis
drug launches
FDA
COVID-19
Zeposia
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »